Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$2.65 – $3.07
Volume20,001
Market cap$10M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$10.13M
Price / earnings
—
Price / book
1.32×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.13×
Profitability
Earnings per share
-$3.65
Return on assets
-117%
Return on equity
-157.29%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.68×
Quick ratio
3.68×
Cash ratio
3.29×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$9.07M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for INTS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.19M
$1.25M
$1.33M
$1.64M
$1.18M
$1.16M
$1.21M
$1.24M
Research and development
$2.43M
$1.83M
$1.2M
$1.5M
$1.55M
$1.54M
$2.19M
$1.97M
Total operating expenses
$3.62M
$3.08M
$2.53M
$3.14M
$2.73M
$2.71M
$3.39M
$3.2M
Operating income
-$3.62M
-$3.08M
-$2.53M
-$3.14M
-$2.73M
-$2.71M
-$3.39M
-$3.2M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$3.54M
-$3.01M
-$2.43M
-$3.05M
-$2.67M
-$2.54M
-$3.35M
-$3.18M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$3.54M
-$3.01M
-$2.43M
-$3.05M
-$2.67M
-$2.54M
-$3.35M
-$3.18M
Net income attributable to common shareholders
-$3.54M
-$3.01M
-$2.43M
-$3.05M
-$2.67M
-$2.54M
-$3.35M
-$3.18M
EBITDA
-$3.62M
-$3.08M
-$2.53M
-$3.14M
-$2.73M
-$2.71M
-$3.39M
-$3.2M
Basic earnings per share
-$1.09
-$1.11
-$0.96
-$1.30
-$1.55
-$3.36
-$5.51
-$5.52
Diluted earnings per share
-$1.09
-$1.11
-$0.96
-$1.30
-$1.55
-$3.36
-$5.51
-$5.52
Recent news
Company coverage with links to the original publishers.
Intensity Therapeutics will participate in the H.C. Wainwright 27th Annual Global Investment Conference, where CEO Lewis H. Bender will discuss their lead investigational product INT230-6, a novel intratumoral cancer therapy designed to kill tumors and enhance immune system recognition.
Intensity Therapeutics has regained compliance with Nasdaq's minimum Stockholders' Equity Requirement after filing its Q2 2025 report, demonstrating sufficient cash to fund operations into the second half of 2026.
Intensity Therapeutics raised $11.3 million in capital, extended cash runway into late 2026, and continues clinical trials for INT230-6, an intratumoral cancer therapy showing promising early results in tumor reduction and immune system engagement.
Shares of Amtech Systems, Inc. (NASDAQ: ASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales guidance below estimates.
Amtech reported quarterly sales of $27.70 million, missing the analyst consensus estimate of $34.50 million. The company anticipated first-quarter revenue to be between $21 million and $24 million, versus the $34.15 million estimate.
Benchmark analyst Mark Miller downgraded Amtech Systems from Buy to Hold.
Amtech Systems shares fell 30.6% to $4.16 on Thursday.
Here are some other stocks moving in today's mid-day session.
Gainers
Freight Technologies, Inc. (NASDAQ: FRGT) shares jumped 322% to $1.14 after the company announced Amazon Mexico renewed its selection of Fr8App for its logistical solutions.
SRIVARU Holding Limited (NASDAQ: SVMH) rose 74.8% to $0.7000.
XBP Europe Holdings, Inc. (NASDAQ: XBP) shares gained 49% to $8.46 after declining around 20% on Wednesday.
TPI Composites, Inc. (NASDAQ: TPIC) rose 46% to $3.1350 as the company announced refinancing transaction with Oaktree, significantly strengthening company’s liquidity position and enhancing financial flexibility.
Nxu, Inc. (NASDAQ: NXU) rose 43.6% to $0.0280 after the company signed a letter of intent outlining investment in Lynx Motors.
Canterbury Park Holding Corporation (NASDAQ: CPHC) rose 31% to $18.70.
View, Inc. (NASDAQ: VIEW) gained 29% to $5.14.
Hanryu Holdings, Inc. (NASDAQ: HRYU) gained 27.1% to $1.3850 after jumping 28% on Wednesday.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares climbed 23.2% to $1.8603. Esperion said that the FDA updated LDL-C lowering indication for NEXLETOL (bempedoic acid) tablet and NEXLIZET (bempedoic acid and ezetimibe) tablet.
Redfin Corporation (NASDAQ: RDFN) gained 21.8% to $10.26.
Codexis, Inc. (NASDAQ: CDXS) ...
Shares of Nxu, Inc. (NASDAQ: NXU) rose sharply in pre-market trading after the company signed a letter of intent outlining investment in Lynx Motors.
Nxu, shares rose 42.1% to $0.0278 in pre-market trading.
Here are some other stocks moving in pre-market trading.
Gainers
XBP Europe Holdings, Inc. (NASDAQ: XBP) shares rose 150% to $14.20 in pre-market trading after declining around 20% on Wednesday.
Hanryu Holdings, Inc. (NASDAQ: HRYU) gained 34.8% to $1.47 in pre-market trading after jumping 28% on Wednesday.
Meiwu Technology Company Limited (NASDAQ: WNW) shares gained 21.1% to $0.0850 in pre-market trading.
Codexis, Inc. (NASDAQ: CDXS) shares surged 20.5% to $2.52 in pre-market trading. Codexis announced achievement of gram-scale synthesis with its ECO Synthesis platform.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares climbed 15.2% to $1.74 in pre-market trading. Esperion said that the FDA updated LDL-C lowering indication for NEXLETOL (bempedoic acid) tablet and NEXLIZET (bempedoic acid and ezetimibe) tablet.
Blue Water Biotech, Inc. (NASDAQ: BWV) shares rose 14.9% to $0.3109 in pre-market trading after gaining ...
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.